Turkalj, E. M. | bioRxiv Science

bioRxiv2025

Cortical organoids reveal human-specific roles of METTL5 in neurodevelopment via regulation of CHCHD2

METTL5 is a conserved methyltransferase responsible for catalyzing N6-methyladenosine (m6A) modification on 18S ribosomal RNA. Human patients with mutations in METTL5 show severe microcephaly and intellectual disability, which has not been fully recapitulated in animal models. Given its emerging role in neurodevelopment, we sought to investigate METTL5 function in a human-specific context using cortical forebrain organoids derived from human induced pluripotent stem cells. We generated METTL5 knockout organoids and observed a marked delay in neural stem cell proliferation and the timing of neuronal differentiation, suggesting a critical role for METTL5 in the temporal regulation of neurogenesis. Though METTL5 methylates rRNA near the decoding center, the mechanism of this methylation remains highly contested. In our cortical organoids, broad translational changes mirror stress response rather than transcript-specific regulation of translation. Transcriptomic analysis further revealed a significant downregulation of CHCHD2, a nuclear-encoded mitochondrial gene linked to cellular energy metabolism and neurodevelopmental processes. Overexpression of CHCHD2 rescued proliferation defects of METTL5-KO neural progenitor cells, suggesting dysregulation of CHCHD2 is heavily involved in the phenotypes of METTL5 mutant patient brains. These findings highlight a previously uncharacterized link between METTL5, ribosomal RNA modification, and cellular metabolism essential for proper human brain development.

molecular biology↗

bioRxiv2023

Inhibition of muscarinic receptor signaling protects human enteric inhibitory neurons against platin chemotherapy toxicity

GI toxicity is a common dose-limiting adverse effect of platin chemotherapy treatment. Up to 50% of cancer survivors continue to experience symptoms of chronic constipation or diarrhea induced by their chemotherapy for many years after their treatment. This drug toxicity is largely attributed to damage to enteric neurons that innervate the GI tract and control GI motility. The mechanisms responsible for platin-induced enteric neurotoxicity and potential preventative strategies have remained unknown. Here, we use human pluripotent stem cell derived enteric neurons to establish a new model system capable of uncovering the mechanism of platin-induced enteric neuropathy. Utilizing this scalable system, we performed a high throughput screen and identified drug candidates and pathways involved in the disease. Our analyses revealed that excitotoxicity through muscarinic cholinergic signaling is a key driver of platin-induced enteric neuropathy. Using single nuclei transcriptomics and functional assays, we discovered that this disease mechanism leads to increased susceptibility of specific neuronal subtypes, including inhibitory nitrergic neurons, to platins. Histological assessment of the enteric nervous system in platin-treated patients confirmed the selective loss of nitrergic neurons. Finally, we demonstrated that pharmacological and genetic inhibition of muscarinic cholinergic signaling is sufficient to rescue enteric neurons from platin excitotoxicity in vitro and can prevent platin-induced constipation and degeneration of nitrergic neurons in mice. These studies define the mechanisms of platin-induced enteric neuropathy and serve as a framework for uncovering cell type-specific manifestations of cellular stress underlying numerous intractable peripheral neuropathies.

pharmacology and toxicology↗